AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the present application.

IN THE CLAIMS:

1. (Currently Amended) A sustained release preparation of a lipophilic drug, comprising a drug dispersion wherein the lipophilic drug and a water-soluble substance are dispersed, as a solid particle at the body temperature of an animal or a human being to which the preparation is to be administered, in a water-impermeable and biocompatible material,

wherein 1 g of the lipophilic drug requires 1000 ml or more of water to be dissolved.

2. (Previously Presented) The sustained release preparation of a lipophilic drug as claimed in Claim 1, which is a rod preparation comprising a drug dispersion and a coating layer, wherein

in said drug dispersion the lipophilic drug and the water-soluble substance are dispersed, as a solid particle at the body temperature of an animal or a human being to which the preparation is to be administered, in a water-impermeable and biocompatible material,

said coating layer comprises a water-impermeable and biocompatible material which is same as or different from that used for said dispersion, and

said drug dispersion is exposed from the surface of the preparation at one or both end(s) of the axial direction thereof.

3. (Original) The sustained release preparation of a lipophilic drug as claimed in Claim 1 or 2 wherein the water-impermeable and biocompatible material is a biocompatible polymer material.

4. (Original) The sustained release preparation of a lipophilic drug as claimed in Claim 1 or 2 wherein the water-impermeable and biocompatible material is silicone.

5. (Previously Presented) The sustained release preparation of a lipophilic drug as claimed in Claim 1 or 2 wherein the water-soluble substance is an amphipathic substance.

6. (Previously Presented) The sustained release preparation of a lipophilic drug as claimed in Claim 1 or 2 wherein the water-soluble substance is polyethylene glycol, polyoxyethylene polyoxypropylene glycol, or surcrose esters of fatty acids.

7. (Previously Presented) The sustained release preparation of a lipophilic drug as claimed in Claim 1 or 2 wherein the water-soluble substance is sodium lauryl sulfate or sodium desoxycholic acid.

8. (Previously Presented) The sustained release preparation of a lipophilic drug as claimed in Claim 1 or 2 wherein the water-soluble substance is sugars.

9. (Previously Presented) The sustained release preparation of a lipophilic drug as claimed in Claim 1 or 2 wherein the water-soluble substance is an amino acid.

10. (Previously Presented) The sustained release preparation of a lipophilic drug as claimed in Claim 1 or 2 wherein the water-soluble substance is a water-soluble drug.

11. (Previously Presented) The sustained release preparation of a lipophilic drug as claimed in Claim 1 or 2 wherein the lipophilic drug is ivermectin, ceftiofur, dexamethasone, or estradiol.

12. (Previously Presented) The sustained release preparation of a lipophilic drug as claimed in claim 4 wherein the water-soluble substance is an amphipathic substance.

13. (Previously Presented) The sustained release preparation of a lipophilic drug as claimed in claim 4 wherein the water-soluble substance is polyethylene glycol, polyoxyethylene polyoxypropylene glycol, or sucrose esters of fatty acids.

14. (Previously Presented) The sustained release preparation of a lipophilic drug as claimed in claim 4 wherein the water-soluble substance is sodium lauryl sulfate or sodium desoxycholic acid.

15. (Previously Presented) The sustained release preparation of a lipophilic drug as claimed in claim 4 wherein the water-soluble substance is sugars.

16. (Previously Presented) The sustained release preparation of a lipophilic drug as claimed in claim 4 wherein the water-soluble substance is an amino acid.

17. (Previously Presented) The sustained release preparation of a lipophilic drug as claimed in claim 4 wherein the water-soluble substance is a water-soluble drug.

18. (Previously Presented) The sustained release preparation of a lipophilic drug as claimed in claim 4 wherein the lipophilic drug is ivermectin, ceftiofur, dexamethasone, or estradiol.